EpiBiologics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 43

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $107M

  • Investors
  • 15

EpiBiologics General Information

Description

Developer of protein degradation therapeutics designed to address disease-causing proteins through targeted degradation. The company specializes in antibody-based targeted therapies against the membrane and extracellular proteins, leveraging a modular system of bifunctional binding agents with a diverse atlas of tissue-selective surface receptors, enabling researchers to manipulate cellular proteostasis for the treatment of the disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1900 Alameda de las Pulgas
  • Suite 250
  • San Mateo, CA 94403
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 1900 Alameda de las Pulgas
  • Suite 250
  • San Mateo, CA 94403
  • United States
+1 (650)

EpiBiologics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EpiBiologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 31-Oct-2025 $107M Completed Generating Revenue
2. Early Stage VC (Series A) 20-Jul-2023 Completed Generating Revenue
1. Early Stage VC 01-Jan-2022 Completed Startup
To view EpiBiologics’s complete valuation and funding history, request access »

EpiBiologics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view EpiBiologics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

EpiBiologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of protein degradation therapeutics designed to address disease-causing proteins through targeted degradation.
Drug Discovery
San Mateo, CA
43 As of 2026

Cambridge, MA
 

Schlieren, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EpiBiologics Competitors (85)

One of EpiBiologics’s 85 competitors is Exo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exo Therapeutics Venture Capital-Backed Cambridge, MA
ImmunOs Therapeutics Venture Capital-Backed Schlieren, Switzerland
BioTheryx Venture Capital-Backed San Diego, CA
Arvinas Formerly VC-backed New Haven, CT
Plexium Venture Capital-Backed San Diego, CA
You’re viewing 5 of 85 competitors. Get the full list »

EpiBiologics Patents

EpiBiologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026090081-A1 Modified ch1 heterodimeric proteins Pending 21-Oct-2024
US-20260042851-A1 Binding agents and uses thereof Pending 02-Jul-2024
WO-2026011013-A1 Binding agents and uses thereof Pending 02-Jul-2024
AU-2024371022-A1 Compositions and methods of use for binding agents Pending 31-Oct-2023
EP-4801973-A1 Compositions and methods of use for binding agents Pending 31-Oct-2023 C07K16/2878
To view EpiBiologics’s complete patent history, request access »

EpiBiologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EpiBiologics Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aulis Capital Venture Capital Minority
Avego Management PE/Buyout Minority
Johnson & Johnson JJDC Corporate Venture Capital Minority
Novartis Venture Fund Corporate Venture Capital Minority
Roche Venture Fund Corporate Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

EpiBiologics FAQs

  • When was EpiBiologics founded?

    EpiBiologics was founded in 2022.

  • Where is EpiBiologics headquartered?

    EpiBiologics is headquartered in San Mateo, CA.

  • What is the size of EpiBiologics?

    EpiBiologics has 43 total employees.

  • What industry is EpiBiologics in?

    EpiBiologics’s primary industry is Drug Discovery.

  • Is EpiBiologics a private or public company?

    EpiBiologics is a Private company.

  • What is the current valuation of EpiBiologics?

    The current valuation of EpiBiologics is .

  • What is EpiBiologics’s current revenue?

    The current revenue for EpiBiologics is .

  • How much funding has EpiBiologics raised over time?

    EpiBiologics has raised $180M.

  • Who are EpiBiologics’s investors?

    Aulis Capital, Avego Management, Johnson & Johnson JJDC, Novartis Venture Fund, and Roche Venture Fund are 5 of 15 investors who have invested in EpiBiologics.

  • Who are EpiBiologics’s competitors?

    Exo Therapeutics, ImmunOs Therapeutics, BioTheryx, Arvinas, and Plexium are some of the 85 competitors of EpiBiologics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process